How do you choose between steroids, cyclophosphamide, and rituximab for inhibitor elimination in acquired hemophilia A?¶
Answer: Most patients with acquired hemophilia A (AHA) require immunosuppressive therapy (IST) to eradicate the inhibitor. The choice is individualized, weighing the patient's risk factors for infection, the inhibitor titer, and whether rapid eradication is required.
- No high-quality trials compare regimens head-to-head. Where hemostatic therapy is available, the most common cause of morbidity is infection.
- Expert consensus stratifies by FVIII level and inhibitor titer:
- FVIII >1% and <20 BU/mL: steroids alone for 3–4 weeks (prednisone 1 mg/kg); add cyclophosphamide or rituximab if not responding.
- FVIII <1% or >20 BU/mL: steroids plus either rituximab (375 mg/m² weekly × 4) or cyclophosphamide (1–2 mg/kg/day).
- Other second-line options include CyDRi, cyclosporine, tacrolimus, and azathioprine.
- A small RCT found rituximab + steroids gave better response rates than cyclophosphamide + steroids (77% vs. 69%; Am J Hematol 2024).
- Our approach: individualize and optimize risk factors before starting IST, using emicizumab as a hemostatic bridge — it provides stable levels so IST can begin after optimization.
See also the BSH/UKHCDO guideline on acquired coagulation factor inhibitors.
Source: International recommendations on the diagnosis and treatment of acquired hemophilia A